Company intelligence / Profile preview

Revogene Industrial

Zhengzhou, Henan, China

Ownership: Private
Development stage: Other

Overview

Clinical studies of the company's DC-CTL cell therapy have demonstrated safety and initial efficacy in treating solid tumors. Results indicate a significant reduction in regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) following treatment, along with decreased levels of serological tumor markers such as alpha-fetoprotein (AFP), CA199, and CA242 in patients with liver and gastric cancers.

Therapeutic areas: OncologyHematology
Modalities: Dendritic cell therapyCell therapyPeptides
Industry: Biotech

Partnerships

The First Affiliated Hospital of Zhengzhou University

Beyond the preview

Go deeper on Revogene Industrial.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Revogene Industrial.

Explore the full profile